Swiss National Bank Hutchmed (China) LTD Transaction History

Swiss National Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$8.59 - $20.77 $9,449 - $22,847	-1,100 Reduced 0.52%	209,660 $2.65 Million
Q1 2022 May 09, 2022	BUY	$15.52 - $35.65 $448,528 - $1.03 Million	28,900 Added 15.89%	210,760 $3.99 Million
Q3 2021 Nov 08, 2021	BUY	$35.66 - $42.94 $1.33 Million - $1.6 Million	37,173 Added 25.69%	181,860 $6.66 Million
Q2 2021 Aug 06, 2021	BUY	$23.7 - $39.27 $61,620 - $102,102	2,600 Added 1.83%	144,687 $5.68 Million
Q1 2021 May 07, 2021	BUY	$27.01 - $36.8 $521,293 - $710,240	19,300 Added 15.72%	142,087 $4.01 Million
Q4 2019 Feb 06, 2020	SELL	$17.17 - $25.95 $837,896 - $1.27 Million	-48,800 Reduced 28.44%	122,787 $3.08 Million
Q3 2019 Nov 12, 2019	BUY	$17.84 - $22.69 $870,592 - $1.11 Million	48,800 Added 39.74%	171,587 $3.07 Million
Q1 2019 May 10, 2019	BUY	$21.27 - $30.58 $393,495 - $565,730	18,500 Added 17.74%	122,787 $3.76 Million
Q4 2018 Feb 13, 2019	BUY	$23.09 - $37.69 $2.41 Million - $3.93 Million	104,287 New	104,287 $2.41 Million

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.